Kernenergieausstieg 2011

Fabio, Udo Di; Durner, Wolfgang; Wagner, Gerhard

doi:10.5771/9783845250304

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baimel C et al (2015) Orexin/hypocretin role in reward: implications for opioid and other addictions. Selective agonists -[Ala 11 , D-Leu 15 ]orexin-B [77,1918], Nag 26 [1024,1682,1990], YNT-185 [1024,1682,1990] Antagonists SB-649868 (pK i 9.1-9.6) [303,456,524], suvorexant (pK i 8.7-9.3) [303,456,1657], filorexant (pK i 8.4-9.1) [303,456,2554], TCS 1102 (pK i 8.5) [161], almorexant (pK i 7.8-8.5) [303,619,1486,1487,1490], Cp-1 (pK i 7.6-8) [1486,1487] SB-649868 (pK i 8.9-9.8) [303,456], TCS 1102 (pK i 9.7) [161], suvorexant (pK i 8.9-9.5) [303,456,1657], Cp-1 (pK i 8.5-9.3) [1486,1487], filorexant (pK i 8.9-9.1) [303,456,2554] Selective antagonists SB-674042 (70-300-fold selective) (pK i 8.7-9.3) [1294,1486,1487,1490], JH112 (pK i 9.1) [912], SB-334867 (50-150-fold selective) (pK i 7.2-7.9) [1294,<...>…”

Section: Further Reading On Orexin Receptorsmentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

Alexander

Christopoulos

Davenport

et al. 2021

British J Pharmacology

377

274

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15538. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: Further Reading On Orexin Receptorsmentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

Alexander

Christopoulos

Davenport

et al. 2021

British J Pharmacology

377

274

View full text Add to dashboard Cite

show abstract

“…One possibility is to sell the water for reuse. In an Italian example, the investment cost was reduce from 30 €/capita to 5 €/capita when purified water was sold for reuse [11,28]. In the Gdańsk case a refinery owned by Grupa Lotos S.A. is situated close to the site of the WTTP.…”

Section: =094mentioning

confidence: 99%

Towards recommendations for design of wetlands for post-tertiary treatment of waste water in the baltic sea region: Gdańsk case study

et al. 2017

View full text Add to dashboard Cite

There are many challenges that need to be addressed if the far reaching objectives on high environmental status as required in the EU Water Framework Directive and the Marine Strategy Framework Directive will be met in the Baltic Sea Region within the next decade. For wastewater treatment plants (WWTP) this implies, in spite of the many improvements made during the last decade, development and introduction of new technology to further reduce eutrophying compounds, hazardous chemicals and pharmaceuticals. Constructed wetlands when properly designed and operated have been shown to be robust systems with low energy requirements that may not only reduce many types of pollutants but may also provide many additional ecosystem services beyond requirements generally imposed by authorities. For example, they may support and enhance biodiversity and be used to convert brownfield areas in urban landscapes to recreational areas. Reduced cost is possible if treated water is reused in industry or for irrigation. In a project, supported by the Swedish Institute, a https://doi.org/10.15626/Eco-Tech.2014.037Linnaeus ECO-TECH ´14, Kalmar, Sweden, November 24-26, 2014 group of scientists, a water company and water using industry has together with local authorities through workshops, field studies and literature studies worked on finding a general first recommendation on design and operation. In this paper we will present the scientific rational and legal constraints for the general design and operation of a wetland system for post-tertiary treatment of waste water from WWTPs using Gdańsk as an example. The proposal includes a first part, which mainly will be focusing on pollutant and pathogen removal using particle traps and a HSSF wetland on land owned by the WWTP and a second part consisting of a FWS wetland which, in addition to further polishing the water, will enhance biodiversity and provide recreational areas on derelict land owned by the city.

show abstract

The Phase-Out of Nuclear Power in Germany

Mann

2020

APP

View full text Add to dashboard Cite

Over the past 20 years, political attitudes in Germany towards the nuclear industry have been characterised less by consistency than by some major policy shifts, and the same can be said for the legislation that emerged from these attitudes. Although a number of these about-turns were predictable, others were less so because of their dependence on external factors. What now looks likely to be the final1 decision to phase out the civil use of nuclear power in Germany by 31 December 20222 raises a whole host of legal questions. In particular, the procedure followed to implement this phase-out provides ample material for debates on questions of constitutionality. Further matters of jurisprudential interest include the agreements concluded with the nuclear industry before the final phase-out decision was taken and the chronologically close political about-face themselves. Finally, a degree of legal uncertainty still surrounds not only the as-yet still unresolved issue of final repositories but also the resurgent debate over the source of funding for the dismantling of nuclear power plants. After providing an overview of the initial situation and the problems arising in connection with Germany’s phasing out of the civil use of nuclear energy, this paper will place these issues in their proper legal context before evaluating them and highlighting the connection between these points of nuclear law and the current upheaval in German energy policy.

show abstract

Kernenergieausstieg 2011

Cited by 3 publications

References 0 publications

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

Towards recommendations for design of wetlands for post-tertiary treatment of waste water in the baltic sea region: Gdańsk case study

The Phase-Out of Nuclear Power in Germany

Contact Info

Product

Resources

About